$ATOS

ATOSSA GENETICS INC

CIK:0001488039|SEC Filings

Condensed Consolidated Statements of Operations (Current Period Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses
Research and development	$ 4,897	$ 5,502	$ 9,676	$ 9,659
General and administrative	3,797	3,538	8,888	6,795
Total operating expenses	8,694	9,040	18,564	16,454
Operating loss	(8,694)	(9,040)	(18,564)	(16,454)
Interest income	227	645	536	1,365
Other expense, net	(24)	(28)	(52)	(52)
Loss before income taxes	(8,491)	(8,423)	(18,080)	(15,141)
Income tax benefit	0	0	0	0
Net loss	$ (8,491)	$ (8,423)	$ (18,080)	$ (15,141)
Net loss per share of common stock - basic (in dollars per share)	$ (0.95)	$ (0.98)	$ (2.06)	$ (1.76)
Net loss per share of common stock - diluted (in dollars per share)	$ (0.95)	$ (0.98)	$ (2.06)	$ (1.76)
Weighted average shares outstanding used to compute net loss per share- basic (in shares)	8,908,511	8,622,289	8,766,191	8,622,289
Weighted average shares outstanding used to compute net loss per share - diluted (in shares)	8,908,511	8,622,289	8,766,191	8,622,289

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (8,491)	$ (8,423)	$ (18,080)	$ (15,141)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation			1,537	1,359
Depreciation			8	8
Changes in operating assets and liabilities:
Prepaid materials			68	(1,377)
Prepaid expenses and other current assets			(665)	90
Other assets			711	(10)
Accounts payable			(2,317)	1,331
Accrued expenses			73	1,281
Payroll liabilities			(586)	(808)
Other current liabilities			26	49
Net cash used in operating activities			(19,225)	(13,218)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment			0	(9)
Net cash used in investing activities			0	(9)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock and warrants			4,500	0
Offering costs for common stock and warrant issuance			(501)	0
Proceeds from issuance of common stock under the ATM program, net of issuance costs			21	0
Net cash provided by financing activities			4,020	0
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH			(15,205)	(13,227)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE			41,409	71,194
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	26,204	57,967	26,204	57,967
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents	26,094	57,857	26,094	57,857
Restricted cash	110	110	110	110
Total cash, cash equivalents and restricted cash	$ 26,204	$ 57,967	$ 26,204	$ 57,967

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 26,094	$ 41,299
Restricted cash	110	110
Prepaid materials	3,013	3,081
Prepaid expenses and other current assets	1,793	1,128
Total current assets	31,010	45,618
Other assets	1,271	1,990
Total Assets	32,281	47,608
Current liabilities
Accounts payable	1,976	4,293
Accrued expenses	1,380	1,307
Payroll liabilities	972	1,558
Other current liabilities	1,123	1,097
Total current liabilities	5,451	8,255
Total Liabilities	5,451	8,255
Commitments and contingencies (Note 12)
Stockholders' equity
Convertible preferred stock - $0.001 par value; 10,000,000 shares authorized; 577 shares issued and outstanding as of June 30, 2026 and December 31, 2025	0	0
Common stock - $0.18 par value; 350,000,000 shares authorized; 9,979,298 and 8,611,361 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	1,796	1,550
Additional paid-in capital	291,151	285,840
Treasury stock, at cost; 88,003 shares of common stock at June 30, 2026 and December 31, 2025	(1,475)	(1,475)
Accumulated deficit	(264,642)	(246,562)
Total Stockholders' Equity	26,830	39,353
Total Liabilities and Stockholders' Equity	$ 32,281	$ 47,608